Neratinib, a next-generation irreversible small molecule inhibitor of receptor tyrosine kinases (HER1/EGFR, HER2, and HER4), has been recently approved for the treatment of HER2+ breast cancer [3–8]. Here, EGFR is linked to breast carcinoma.